AP NEWS
ADVERTISEMENT
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Related topics
PRESS RELEASE: Paid content from Globe Newswire
Press release content from Globe Newswire. The AP news staff was not involved in its creation.

NGM Bio to Host Conference Call to Discuss Topline Results from 24-Week Phase 2b ALPINE 2/3 ...

May 23, 2021 GMT

SOUTH SAN FRANCISCO, Calif., May 23, 2021 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (Nasdaq: NGM) will host a conference call and live webcast on Monday, May 24, 2021 at 8:30 a.m. ET (5:30 a.m. PT) to discuss topline results from the 24-week Phase 2b ALPINE 2/3 study evaluating 0.3 mg, 1 mg and 3 mg doses of aldafermin versus placebo in patients with non-alcoholic steatohepatitis, or NASH, with stage 2 or 3 liver fibrosis. Conference call and webcast details are as follows:

Live Conference Call
Domestic Callers: (844) 873-0551
International Callers: (602) 563-8472
Passcode: 9393531

Live and Archived Webcast                                   
For the live or archived webcast, please visit the “Investors & Media” section of NGM’s website at  https://ir.ngmbio.com/. The webcast will be archived for 30 days.

ADVERTISEMENT

Archived Conference Call  
Domestic Callers: (855) 859-2056
International Callers: (404) 537-3406
Passcode: 9393531

The archived conference call will be available for 30 days.

About NGM Biopharmaceuticals, Inc.

NGM is a biopharmaceutical company focused on discovering and developing novel therapeutics based on scientific understanding of key biological pathways underlying liver and metabolic diseases, retinal diseases and cancer. We leverage our biology-centric drug discovery approach to uncover novel mechanisms of action and generate proprietary insights that enable us to move rapidly into proof-of-concept studies and deliver potential first-in-class medicines to patients. At NGM, we aspire to operate one of the most productive research and development engines in the biopharmaceutical industry. Visit us at www.ngmbio.com  for more information.

Investor Contact:
Alex Schwartz
ir@ngmbio.com  
Media Contact:
Liz Melone
media@ngmbio.com